Maise Høigaard Fredgart

Maise Høigaard Fredgart

Auto-generated profile, based on publicly available information

Maise Høigaard Fredgart

Department of Cardiology, Odense Universitetshospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Circulation
Verified
Journal Article
Open access
PDF file
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
Sören MöllerSören Möller
Sören Möller
KØKristian A. Øvrehus
Kristian A. Øvrehus
SASøren Auscher
Søren Auscher
JDJordi S. Sanchez Dahl
Jordi S. Sanchez Dahl
Background: Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis. Methods: In a randomized, double-blind, multicenter trial, men from the community with an AVC score >300 arbitrary units (AU) on cardiac noncontrast computer tomography were randomized to daily treatment with tablet 720 µg MK-7 plus 25 µg vitamin D or matching placebo for 24 months. The primary outcome was the change in AVC score. Selected secondary outcomes included change in aortic valve area and peak aortic jet velocity on echocardiography, heart valve surgery, change in aortic and coronary artery calcification, and change in dp-ucMGP (dephosphorylated-undercarboxylated matrix Gla-protein). Safety outcomes included all-cause death and cardiovascular events. Results: From February 1, 2018, to March 21, 2019, 365 men were randomized. Mean age was 71.0 (±4.4) years. The mean (95% CI) increase in AVC score was 275 AU (95% CI, 225–326 AU) and 292 AU (95% CI, 246–338 AU) in the intervention and placebo groups, respectively. The mean difference on AVC progression was 17 AU (95% CI, –86 to 53 AU; P =0.64). The mean change in aortic valve area was 0.02 cm 2 (95% CI, –0.09 to 0.12 cm 2 ; P =0.78) and in peak aortic jet velocity was 0.04 m/s (95% CI, –0.11 to 0.02 m/s; P =0.21). The progression in aortic and coronary artery calcification score was not significantly different between patients treated with MK-7 plus vitamin D and patients receiving placebo. There was no difference in the rate of heart valve surgery (1 versus 2 patients; P =0.99), all-cause death (1 versus 4 patients; P =0.37), or cardiovascular events (10 versus 10 patients; P =0.99). Compared with patients in the placebo arm, a significant reduction in dp-ucMGP was observed with MK-7 plus vitamin D (–212 pmol/L versus 45 pmol/L; P 300 AU, 2 years MK-7 plus vitamin D supplementation did not influence AVC progression. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03243890.

23 August 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
NFNiels Erik Frandsen
Niels Erik Frandsen
MFMaise Høigaard Fredgart
Maise Høigaard Fredgart
KØKristian A Øvrehus
Kristian A Øvrehus
JDJordi Sanchez Dahl
Jordi Sanchez Dahl
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
Introduction Aortic stenosis is a common heart valve disease, and due to the growing elderly population, the prevalence is increasing. The disease is progressive with increasing calcification of the valve cusps. A few attempts with medical preventive treatment have failed; thus, presently, the only effective treatment of aortic stenosis is surgery. This study will examine the effect of menaquinone-7 (MK-7) supplementation on progression of aortic valve calcification (AVC). We hypothesise that MK-7 supplementation will slow down the calcification process. Methods and analysis In this multicenter and double-blinded, placebo-controlled study, 400 men aged 65–74 years with substantial AVC are randomised (1:1) to treatment with MK-7 (720 µg/day) supplemented by the recommended daily dose of vitamin D (25 µg/day) or placebo treatment (no active treatment) for 2 years. Exclusion criteria are treatment with vitamin K antagonist or coagulation disorders. To evaluate AVC score, a non-contrast CT scan is performed at baseline and repeated after 12 and 24 months of follow-up. Primary outcome is difference in AVC score from baseline to follow-up at 2 years. Intention-to-treat principle is used for all analyses. Ethics and dissemination There are no reported adverse effects associated with the use of MK-7. The protocol is approved by the Regional Scientific Ethical Committee for Southern Denmark (S-20170059) and the Data Protection Agency (17/19010). It is conducted in accordance with the Declaration of Helsinki. Positive as well as negative findings will be reported. Trial registration number NCT03243890.

6 April 2016 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
TLThomas M Leurgans
Thomas M Leurgans
Maria BloksgaardMaria Bloksgaard
Maria Bloksgaard
JBJonathan Richard Brewer
Jonathan Richard Brewer
LBLuis A. Bagatolli
Luis A. Bagatolli
MFMaise H Fredgart
Maise H Fredgart
JMJo G R De Mey
Jo G R De Mey

1 January 2022 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
JRJeppe Holm Rasmussen
Jeppe Holm Rasmussen
MFMaise Hoeigaard Fredgart
Maise Hoeigaard Fredgart
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
JJJens Brock Johansen
Jens Brock Johansen
NSNiels Sandgaard
Niels Sandgaard
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
Rasmussen JH, et al. J Cardiovasc Imaging. 2022 Jan;30(1):62-75. https://doi.org/10.4250/jcvi.2021.0110

1 July 2018 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Open access
MFMaise Høigaard Fredgart
Maise Høigaard Fredgart
RCRasmus Carter-Storch
Rasmus Carter-Storch
JMJacob Eifer Møller
Jacob Eifer Møller
KØKristian Altern Øvrehus
Kristian Altern Øvrehus
RPRedi Pecini
Redi Pecini
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
Cardiac magnetic resonance imaging (MRI) is considered the gold standard for assessment of left atrial (LA) volume. We assessed the feasibility of evaluating LA volume using 3D non-contrast computed tomography (NCCT). Furthermore, since manual tracing of LA volume is time consuming, we evaluated the accuracy of the LA area using 2D NCCT imaging for LA volume assessment. MRI and NCCT imaging were performed in 69 patients before and one year after aortic valve replacement. In 3D MRI and 3D NCCT, each slice was manually traced, excluding the pulmonary veins and atrial appendage, and multiplied by slice spacing, thus generating a measure of LA volume. The LA volume was indexed to body surface area. On 2D NCCT, the largest axial cross-section LA area was traced manually. The mean LA volume was 102 ± 28 ml in MRI compared with 103 ± 28 ml in 3D NCCT. 3D NCCT showed good agreement with MRI measurements (mean difference -0.7 ml/m2; 95% confidence interval (CI) -2.2 to 0.9). By Bland-Altman, 3D NCCT also showed good agreement with MRI (limits of agreement: -18.7-17.4 ml/m2). Furthermore, good correlation was found between 2D NCCT and 3D NCCT LA volume (r = 0.93). 2D and 3D measurements of LA volume in non-contrast computed tomography are feasible and accurate.

1 April 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
MFMaise Hoeigaard Fredgart
Maise Hoeigaard Fredgart
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
ABAxel Brandes
Axel Brandes
FSFlemming Hald Steffensen
Flemming Hald Steffensen
LFLars Frost
Lars Frost
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen